A gene therapy treatment of 12 patients between the ages of 8-44 years suffering RPE65-associated Leber’s Congenital Amaurosis (LCA) has been shown to improve vision… Read More »Phase 1 dose escalation study on gene therapy treatment for LCA shows importance of early treatment
Multi-centre Phase III clinical trial shows benefits of corticosteroid in reducing vision loss in ce
A multicenter, prospective, randomized clinical trial designed to compare 1-mg and 4-mg doses of intravitreal triamcinoclone with standard care for treatment of vision loss associated… Read More »Multi-centre Phase III clinical trial shows benefits of corticosteroid in reducing vision loss in ce
Researchers based at the Rotterdam Eye Hospital in the Netherlands have announced the first ever results reporting an association between the thickness of the retinal… Read More »Retinal nerve fiber layer (RNFL) thickness found to be associated with cognitive functioning.
A new study by a research group at Bilim University, Istanbul, has reported positive results in a cohort of retinitis pigmentosa (RP) patients treated with… Read More »Treatment of retinitis pigmentosa with bevacizumab (Avastin)
A US study led by the Scheie Eye Institute in Pennsylvania has identified regions of normal and damaged retinal architecture in a cohort of USH1B… Read More »Regional retinal damage in Usher syndrome patients may guide treatment strategy
Recent advances in retinal gene therapy, notably in three concurrent human trials addressing LCA (Leber’s congenital amurosis), have focused significant attention on the wider potential… Read More »Viral delivery particles may persist in the retina for up to 6 years